MedTrace Logo

The Relevance Between the microRNA-30e in Plasma and the Prognosis of Schizophrenia Patients

NCT03007303 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2020-01-30

No results posted yet for this study

Summary

This study investigates the relationship of circulating microRNA-30e and schizophrenia, and shows the relevance of the aberrant microRNA-30e expression in plasma with the variation disease status.

Conditions

Interventions

DRUG

Atypical Antipsychotic

Olanzapine: tablet ,5-20mg, Po q.d. Risperidone: tablet ,1-3 mg, Po q.d. Quetiapine: tablet ,100-400mg, Po b.i.d. ziprasidone : tablet ,40 -80mg, Po b.i.d.

OTHER

atypical antipsychotic combined with MECT

The schizophrenia who matches the indications such as severe negativism, refused to eating or stupor may be treated with antipsychotic combined with MECT, the frequency and times of MECT depend on the state of illness

Sponsors & Collaborators

  • TAKARA BIOTECHNOLOGY(DALIAN)CO.,LTD.

    collaborator UNKNOWN

  • Dalian Seventh People's Hospital

    lead OTHER

Principal Investigators

  • Shoufu Xie, postgraduate · Dalian Seventh People's Hospital

Eligibility

Min Age
17 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2020-03-31
Completion
2020-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03007303 on ClinicalTrials.gov